Eli Lilly (incl. Loxo)
Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.
Abemaciclib, selpercatinib, imlunestrant (Inluriyo 2025), pirtobrutinib, olomorasib (KRAS G12C), Scorpion PI3Kα-mutant-selective programme.
Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer.
Selpercatinib is a selective RET inhibitor approved for any tumour with a RET fusion, with a further label update in July 2026.
An antibody that blocks the EGFR growth receptor. It works in bowel cancers with a normal RAS gene, especially left-sided ones, and is a key partner in the BRAF combination.
A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.
Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation.
Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer.
A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025.
An antibody that blocks the VEGF receptor, approved in liver cancer only for patients with a high AFP blood level, the first biomarker-selected HCC drug.
Patients with newly diagnosed advanced clear-cell kidney cancer should receive an immunotherapy-based combination; lenvatinib plus pembrolizumab gives the highest response rate and longest PFS of the available options, at the cost of more side effects requiring dose adjustment. Sunitinib alone is no longer an appropriate standard. Choosing among the combinations depends on risk group, symptoms, comorbidity and the value placed on treatment-free survival, which favours nivolumab plus ipilimumab in intermediate and poor risk.
Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.
Pages like this
not linked directly; found by shared links- Key paperIARC verdict: excess body fat causes 13 cancers
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, Thyroid cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer.
- TermObesity-related cancers (IARC list of 13)
Shares GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer, GLP-1 receptor agonists and obesity-related cancer risk, Thyroid cancer, Hepatocellular carcinoma.
- IdeaLink bariatric and GLP-1 registries to cancer registries in every country that has both
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, GLP-1 receptor agonists and obesity-related cancer risk, Hepatocellular carcinoma, Colorectal cancer.
- InstitutionNational Cancer Center Korea
Shares Thyroid cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- TrialEMBER-3
Shares Imlunestrant, Abemaciclib, HR-positive / HER2-negative breast cancer.
- PairingOral SERD + CDK4/6 inhibitor after ESR1 emergence
Shares Imlunestrant, Abemaciclib, HR-positive / HER2-negative breast cancer.
- InstitutionFirst Affiliated Hospital of Sun Yat-sen University
Shares Thyroid cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
- TrialmonarchE
Shares monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer, Abemaciclib, HR-positive / HER2-negative breast cancer.